U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2002
144
Substance Class Protein
Created
by admin
on Mon Mar 31 20:42:42 GMT 2025
Edited
by admin
on Mon Mar 31 20:42:42 GMT 2025
Protein Type MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type IGG1
Sequence Origin MOUSE
Sequence Type COMPLETE
Record UNII
4Q52C550XK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZEVALIN
Preferred Name English
IBRITUMOMAB TIUXETAN
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
IBRITUMOMAB TIUXETAN [USAN]
Common Name English
IBRITUMOMAB TIUXETAN [VANDF]
Common Name English
ibritumomab tiuxetan [INN]
Common Name English
Ibritumomab tiuxetan [WHO-DD]
Common Name English
IDEC-Y2B8
Code English
MAB MURINE (IGG1) ANTI P19437 (CD20_MOUSE)
Common Name English
IBRITUMOMAB TIUXETAN [EMA EPAR]
Common Name English
IBRITUMOMAB TIUXETAN [PURPLE BOOK CDER]
Common Name English
IBRITUMOMAB TIUXETAN [MART.]
Common Name English
IDEC-IN2B8
Code English
IDEC-129
Code English
IBRITUMOMAB TIUXETAN [JAN]
Common Name English
IBRITUMOMAB TIUXETAN [MI]
Common Name English
IDEC-Y2B8 IDEC-129
Code English
Classification Tree Code System Code
NDF-RT N0000175658
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
EMA ASSESSMENT REPORTS ZEVALIN (AUTHORIZED: LYMPHOMA, FOLLICULAR)
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
NDF-RT N0000000205
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
NCI_THESAURUS C1512
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
NDF-RT N0000175078
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
FDA ORPHAN DRUG 84894
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
Code System Code Type Description
MESH
C422802
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
IUPHAR
6777
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
EVMPD
SUB20031
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
INN
7873
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
NCI_THESAURUS
C29981
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
DRUG CENTRAL
4984
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
CAS
206181-63-7
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
SMS_ID
100000090284
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201606
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
PUBCHEM
74890578
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
MERCK INDEX
m6187
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY Merck Index
WIKIPEDIA
IBRITUMOMAB TIUXETAN
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
RXCUI
262323
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB00078
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
FDA UNII
4Q52C550XK
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
ChEMBL
CHEMBL2108667
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
USAN
JJ-95
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
DAILYMED
4Q52C550XK
Created by admin on Mon Mar 31 20:42:42 GMT 2025 , Edited by admin on Mon Mar 31 20:42:42 GMT 2025
PRIMARY
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_295
N 2_295
Related Record Type Details
HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I
TARGET -> AGONIST
B-LYMPHOCYTE ANTIGEN CD20
TARGET->LIGAND
Related Record Type Details
IBRITUMOMAB TIUXETAN
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
CONJUGATE TIUXETAN HKM5WZS29Q
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:ESTIMATED CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966